New drug price law could help Part D en­rollees who can't fill can­cer treat­ments due to costs, White House says

The White House’s Coun­cil of Eco­nom­ic Ad­vi­sors said late last week that health cov­er­age can come in unique ways, such as with new­ly passed fed­er­al leg­is­la­tion, the In­fla­tion Re­duc­tion Act. And in cit­ing new da­ta, it re­veals some in­sights in­to can­cer pa­tients, a key em­pha­sis for the Biden Ad­min­is­tra­tion thanks to Pres­i­dent Biden’s re­vived Can­cer Moon­shot.

In a blog post pub­lished Fri­day, the White House high­light­ed re­duc­ing pre­scrip­tion drug costs for Medicare ben­e­fi­cia­ries as one of three ways it sees ac­cess to health­care in­creas­ing. The IRA specif­i­cal­ly caps out-of-pock­et costs for se­niors at $2,000 a year, in ad­di­tion to grant­i­ng Medicare the au­thor­i­ty to ne­go­ti­ate drug prices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER